Clinical Trial Update: CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating difelikefalin (CR845) for pruritus in advanced chronic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Pruritus

Drugs mentioned

• Difelikefalin (CR845) (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Chronic Kidney Diseases, Pruritus | Phase 3 | Status: TERMINATED